|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.5 USD | -16.80% |
|
-16.02% | +2.34% |
| May. 10 | Needham Downgrades Collegium Pharmaceutical to Hold From Buy | MT |
| May. 10 | Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39 | MT |
Collegium Pharmaceutical, Inc. reaffirmed earnings guidance for the year 2023. For the year 2023, the company expects product revenues, net of $565.0 million to $580.0 million.
| 1st Jan change | Capi. | |
|---|---|---|
| +2.34% | 1.03B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
COLLEGIUM PHARMACEUTICAL, INC. 
